-
1.发明授权公开(公告)号：US08404747B2
公开(公告)日：2013-03-26
申请号：US11076093
申请日：2005-03-07
IPC分类号： A61K31/445 , A61K31/4015 , A61K31/21 , A61K31/277
CPC分类号： C07C311/46 , A61K31/21 , A61K31/277 , A61K31/4015 , A61K31/445 , C07C311/44 , C07C2601/16 , C07D209/56 , C07D209/80 , C07D215/40 , C07D215/42 , C07D217/24 , C07D221/06 , C07D223/02 , C07D295/20 , C07D295/26 , C07D333/36 , C07D333/38 , C07D401/06
摘要： The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another.
摘要翻译： 本发明部分基于我们进行的测定，其显示可用于治疗或预防以一种蛋白质与另一种蛋白质的异常或不期望的结合为特征的疾病的化合物。
-
公开(公告)号：US07179897B2
公开(公告)日：2007-02-20
申请号：US10194584
申请日：2002-07-12
IPC分类号： C07H21/04
CPC分类号： G01N33/6896
摘要： Methods of identifying compounds that disrupt aggregation of aggregation-disposed polypeptides, such as huntingtin or beta-amyloid protein, are disclosed. Furthermore, an artificial polypeptide that contains an extended polyglutamine region and DNA that encodes the polypeptide are also disclosed.
摘要翻译： 公开了鉴定破坏凝集排列的多肽（例如亨廷妥或β-淀粉样蛋白）聚集的化合物的方法。 此外，还公开了含有扩展的多聚谷氨酰胺区域的人工多肽和编码多肽的DNA。
-
公开(公告)号：US07015012B2
公开(公告)日：2006-03-21
申请号：US10470765
申请日：2002-02-11
IPC分类号： C12Q1/02
CPC分类号： G01N33/5058 , A61K31/18 , A61K31/215 , A61K31/235 , A61K31/428 , G01N33/5008 , G01N33/502 , G01N33/582 , G01N33/6803 , G01N33/6896 , G01N2500/02
摘要： The present invention is based, in part, on the discovery of methods for identifying compounds that mediate (by promoting or inhibiting) protein-protein interaction (e.g., aggregation, dimerization, or other physiologically significant association). Compounds that mediate such interaction, which are also within the scope of the invention, can be used to treat Alzheimer's disease, disorders associated with expanded CAG repeats (such as Huntington's disease), and disorders in which polyglutamine-containing transcription factors or coactivators are undesirably active (e.g., disorders associated with homodimerization of jun or hexamerization of p53.
摘要翻译： 本发明部分地基于用于鉴定介导（通过促进或抑制）蛋白质 - 蛋白质相互作用（例如，聚集，二聚化或其它生理学显着关联）的化合物的方法的发现。 介导这种相互作用的化合物，其也在本发明的范围内，可用于治疗阿尔茨海默病，与扩大的CAG重复（例如亨廷顿病）相关的病症，以及其中含有多聚谷氨酰胺的转录因子或共激活因子是不期望的疾病 活性（例如，与p53的jun或hexamerization的同二聚化相关的障碍。
-
公开(公告)号：US06420122B1
公开(公告)日：2002-07-16
申请号：US09405048
申请日：1999-09-27
IPC分类号： G01N3353
CPC分类号： G01N33/6896
摘要： Methods of identifying compounds that disrupt aggregation of aggregation-disposed polypeptides, such as huntingtin or beta-amyloid protein, are disclosed. Furthermore, an artificial polypeptide that contains an extended polyglutamine region and DNA that encodes the polypeptide are also disclosed.
摘要翻译： 公开了鉴定破坏凝集排列的多肽（例如亨廷妥或β-淀粉样蛋白）聚集的化合物的方法。 此外，还公开了含有扩展的多聚谷氨酰胺区域的人工多肽和编码多肽的DNA。
-
5.发明申请COMPOSITIONS AND METHODS FOR MODULATING POLY(ADP-RIBOSE) POLYMERASE ACTIVITY 审中-公开用于调节聚（ADP-RIBOSE）聚合酶活性的组合物和方法公开(公告)号：US20100069372A1
公开(公告)日：2010-03-18
申请号：US12559036
申请日：2009-09-14
申请人： Aleksey G. Kazantsev
发明人： Aleksey G. Kazantsev
IPC分类号： A61K31/5513 , A61P25/00 , A61P25/16 , A61P25/28
CPC分类号： A61K31/551 , A61K31/365 , A61K31/403 , A61K31/553
摘要： The present invention is based, in part, on assays we conducted that revealed compounds that modulate (e.g., inhibit) PARP-1 and are therefore useful in treating or preventing diseases characterized by abnormal PARP-1 activity (e.g., undesirable PARP-1 activity).
摘要翻译： 本发明部分基于我们进行的测定，其显示出调节（例如抑制）PARP-1的化合物，因此可用于治疗或预防以PARP-1异常活动为特征的疾病（例如不期望的PARP-1活性 ）。
-
公开(公告)号：US20090069559A1
公开(公告)日：2009-03-12
申请号：US12100080
申请日：2008-04-09
申请人： Aleksey G. Kazantsev
发明人： Aleksey G. Kazantsev
IPC分类号： C07D401/12 , C07D401/10 , C07D413/10
CPC分类号： C07D405/12 , C07D295/26 , C07D401/12
摘要： The present invention is based, in part, on our discovery of compounds that inhibit an activity of a sirtuin (e.g., compounds that inhibit or preferentially inhibit an activity of SIRT2) and are therefore believed useful in the treatment or prevention of diseases associated with sirtuin activity. These diseases include, but are not limited to, neurological disorders such as Parkinson's Disease (PD).
摘要翻译： 本发明部分基于我们发现抑制沉默调节蛋白的活性的化合物（例如，抑制或优先抑制SIRT2活性的化合物），因此被认为可用于治疗或预防与sirtuin相关的疾病 活动。 这些疾病包括但不限于神经障碍如帕金森病（PD）。
-
公开(公告)号：US20090259044A1
公开(公告)日：2009-10-15
申请号：US12143478
申请日：2008-06-20
申请人： Aleksey G. Kazantsev
发明人： Aleksey G. Kazantsev
IPC分类号： C07D215/38
CPC分类号： C07D401/12 , C07D405/12
摘要： The present invention is based, in part, on our discovery of compounds that inhibit an activity of a sirtuin (e.g., compounds that inhibit or preferentially inhibit an activity of SIRT2) and are therefore believed useful in the treatment or prevention of diseases associated with sirtuin activity. These diseases include, but are not limited to, neurological disorders such as Parkinson's Disease (PD).
摘要翻译： 本发明部分基于我们发现抑制沉默调节蛋白的活性的化合物（例如，抑制或优先抑制SIRT2活性的化合物），因此被认为可用于治疗或预防与sirtuin相关的疾病 活动。 这些疾病包括但不限于神经障碍如帕金森病（PD）。
-
公开(公告)号：US08153803B2
公开(公告)日：2012-04-10
申请号：US12143478
申请日：2008-06-20
申请人： Aleksey G. Kazantsev
发明人： Aleksey G. Kazantsev
IPC分类号： C07D215/38
CPC分类号： C07D401/12 , C07D405/12
摘要： The present invention is based, in part, on our discovery of compounds that inhibit an activity of a sirtuin (e.g., compounds that inhibit or preferentially inhibit an activity of SIRT2) and are therefore believed useful in the treatment or prevention of diseases associated with sirtuin activity. These diseases include, but are not limited to, neurological disorders such as Parkinson's Disease (PD).
摘要翻译： 本发明部分基于我们发现抑制沉默调节蛋白的活性的化合物（例如，抑制或优先抑制SIRT2活性的化合物），因此被认为可用于治疗或预防与sirtuin相关的疾病 活动。 这些疾病包括但不限于神经障碍如帕金森病（PD）。
-
公开(公告)号：US20080021063A1
公开(公告)日：2008-01-24
申请号：US11488293
申请日：2006-07-18
申请人： Aleksey G. Kazantsev
发明人： Aleksey G. Kazantsev
IPC分类号： A61K31/47 , C07D215/00 , C07D215/38
CPC分类号： C07D405/12 , C07D295/26 , C07D401/12
摘要： The present invention is based, in part, on our discovery of compounds that inhibit an activity of a sirtuin (e.g., compounds that inhibit or preferentially inhibit an activity of SIRT2) and are therefore believed useful in the treatment or prevention of diseases associated with sirtuin activity. These diseases include, but are not limited to, neurological disorders such as Parkinson's Disease (PD).
摘要翻译： 本发明部分基于我们发现抑制沉默调节蛋白的活性的化合物（例如，抑制或优先抑制SIRT2活性的化合物），因此被认为可用于治疗或预防与sirtuin相关的疾病 活动。 这些疾病包括但不限于神经障碍如帕金森病（PD）。
-
公开(公告)号：US06569994B1
公开(公告)日：2003-05-27
申请号：US09105254
申请日：1998-06-26
IPC分类号： C07K1700
CPC分类号： C07K14/705 , C07K2319/00 , C12N2799/026
摘要： The present invention relates to a novel member of the blue-fight photoreceptor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human hCRY2 receptor. hCRY2 polypeptides are also provided as are vectors, host cells, antibodies, and recombinant methods for producing the same.
摘要翻译： 本发明涉及蓝色受感染家族的新型成员。 特别地，提供编码人hCRY2受体的分离的核酸分子。 还提供hCRY2多肽，载体，宿主细胞，抗体和用于制备它们的重组方法。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.028 秒)
